Corona Remedies Ltd

Corona Remedies Ltd share price inched up 0.38% to Rs 2097.6 after the company's net profit soared by 32.61% to Rs 60.11 crore, while revenue from operations gained 19.64% to Rs 422.43 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 5.89%. It has marginally improved by 2.79% over last one week and jumped by 15.59% in last one month while the market capitalization of Corona Remedies Ltd has softened by 0.78% and 21.60% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.36 crore in Q2 FY26, jumping 32.41% year-on-year, and expanding by 46.80% quarter-on-quarter. EBITDA came in at Rs 90 crore, surging by 32.79% YoY and rallying 55.38% sequentially. Total expenses advancing by 13.66% to Rs 342.54 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 32.65 crore, increasing 17.74% YoY, while employee benefits expense was at Rs 122.09 crore, witnessing a strong rise of 14.50% YoY. For the TTM ended FY26, revenue from operations grew 17.28% to Rs 1403.18 crore, while net profit jumped 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA jumped by 23376% to Rs 282.79 crore, and PBT soared 21.10% to Rs 240.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd surged by 45.95% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.81% during the same period.

Corona Remedies Ltd share price softened by 0.77% to Rs 2089.65. The Company's net profit soared by 32.61% to Rs 60.11 crore, while revenue from operations gained 19.64% to Rs 422.43 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has inched up 2.79% over last one week and surged by 15.59% in last one month while the market capitalization of Corona Remedies Ltd has slipped by 0.78% and 21.60% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.36 crore in Q2 FY26, surging by 32.41% year-on-year, and rallying 46.80% quarter-on-quarter. EBITDA came in at Rs 90 crore, expanding by 32.79% YoY and jumping 55.38% sequentially. Total expenses increased by 13.66% to Rs 342.54 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 32.65 crore, advancing by 17.74% YoY, while employee benefits expense was at Rs 122.09 crore, witnessing a strong rise of 14.50% YoY. For the TTM ended FY26, revenue from operations grew 17.28% to Rs 1403.18 crore, while net profit saw a strong growth of 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA surged by 23376% to Rs 282.79 crore, and PBT surged 21.10% to Rs 240.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd rallied 45.40% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.

CORONA Remedies Limited announced its unaudited financial results for the first quarter of fiscal year 2027, reporting revenue of Rs 422.4 crore, a 21.9% year-over-year increase, and profit after tax of Rs 60.1 crore, a 30.1% year-over-year increase. The company, a leading India-focused branded pharmaceutical company, also inaugurated a European Union Good Manufacturing Practice (EU-GMP) approved Female Hormone Manufacturing Facility in Ahmedabad and initiated the integration of the acquired brand, Wokadine.

Corona Remedies will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Corona Remedies announced that the 22th Annual General Meeting(AGM) of the company will be held on 9 July 2026.

Corona Remedies announced that the Board of Directors of the Company at its meeting held on 11 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Corona Remedies has fixed 19 June 2026 as record date for final dividend of Rs 10 per equity share of Rs 10 for FY 2025-26. The dividend shall be paid on or before 07 August 2026.

Net profit of Corona Remedies rose 43.68% to Rs 45.33 crore in the quarter ended March 2026 as against Rs 31.55 crore during the previous quarter ended March 2025. Sales rose 20.23% to Rs 353.09 crore in the quarter ended March 2026 as against Rs 293.69 crore during the previous quarter ended March 2025. For the full year,net profit rose 23.88% to Rs 185.12 crore in the year ended March 2026 as against Rs 149.43 crore during the previous year ended March 2025. Sales rose 17.28% to Rs 1403.18 crore in the year ended March 2026 as against Rs 1196.42 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales353.09293.69 20 1403.181196.42 17 OPM %17.5618.46 -20.9120.06 - PBDT65.0353.65 21 297.39235.69 26 PBT54.7443.61 26 259.52198.53 31 NP45.3331.55 44 185.12149.43 24 Powered by Capital Market - Live

Corona Remedies will hold a meeting of the Board of Directors of the Company on 11 May 2026.

The Wokadine brand is an antiseptic and disinfectant containing Povidone-Iodine, used to treat or prevent skin infections in minor cuts, burns, wounds, and abrasions. Wokadine ranked second in the Povidone Iodine market in India according to Pharmatrac MAT February 2026 data, is expected to support Corona Remedies' strategy of expanding its specialty care portfolio and strengthening its presence among surgeons, ENT specialists, general physicians, and gynaecologists. According to the same report, the Indian Povidone Iodine market is estimated at Rs 648 crore. The company's sales & marketing team along with extensive distribution network will work to ensure that this newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban and rural areas. Wokadine comprises of 14 SKUs having different applications, helping clinicians treat the ailing community. This acquisition will be fully funded through company's internal accruals and cash. Tejas Kothari, vice president ' corporate strategy & business development said: 'At CORONA Remedies, we continuously assess both organic and inorganic growth opportunities, focusing on strengthening our brands by leveraging CORONA's extensive reach, strong trust among doctors and the medical fraternity, a pan-India distribution network, and a dedicated sales and marketing team. The company's consolidated net profit tumbled 8.19% to Rs 41.27 crore despite 15.03% jump in revenue from operations to Rs 342.42 crore in Q3 December 2025 over Q3 December 2024. The counter fell 1.52% to settle at Rs 1,556.15 on the BSE. The stock market will remain closed today on account of Mahavir Jayanti.Powered by Capital Market - Live